March 13, 2023
Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Matthew R. Ritter; Aaron L. Parker; Elliot C. Cook
[Editor’s Note: Given the total decline of CBM Final Written Decisions on a monthly basis since the sunset of the CBM program in September 2020, we will no longer list CBMs in our monthly statistics charts. We will continue to include historical CBM data in our cumulative PTAB statistics.]
In January, a relatively busy month at the PTAB, 278 (28%) of instituted claims survived review across 71 IPR and PGR Final Written Decisions, including decisions following remand from the Federal Circuit. The PTAB cancelled 651 (65.56%) instituted claims, and patent owners conceded 64 (6.45%) instituted claims through motions to amend or disclaimer in cases reaching a final decision. For comparison, the cumulative average survival rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 73%.
On a per-case basis, no instituted or substitute claims survived in 45 (63.38%) decisions, all instituted claims survived in 13 (18.31%) decisions, and a mixed outcome occurred in 13 (18.31%) decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.
Through January 31, 2023, the PTAB has cumulatively granted 595 (17.18%) proposed substitute claims in motions to amend while denying 2,868 (82.82%) proposed substitute claims.
The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through January 31, 2023, broken down by technology center, is as follows:
The cumulative number of Final Written Decisions through January 31, 2023, separated by technology center, is as follows:
Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.